{
  "id": 16597309,
  "title": "Eris Q2 FY27 slides: profit surges 39% on diabetes strength",
  "url": "https://urgent.news/2026/10/26/eris-q2-fy27-slides-profit-surges-39-on-diabetes-strength",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-10-26T11:57:03.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/company-news/eris-q2-fy27-slides-profit-surges-39-on-diabetes-strength-93CH-4972378"
  },
  "original_language": "en",
  "account": "Eris Lifesciences reported a 39.2% year-over-year surge in profit after tax (PAT) during Q2 FY27, reaching ₹187 crore. The company's revenue grew 12.6% to ₹892 crore. Despite strong performance, the stock traded near its 52-week low, closing at ₹1,100 with a 0.41% gain. Analysts view the stock as potentially undervalued. The company's strategy and operations played a crucial role in this growth, with EBITDA reaching ₹309 crore in Q2, up 7.3% from the previous year. The DBF segment, the core of Eris's business, experienced 14.1% year-over-year revenue growth, with organic growth accelerating to 16.5% when excluding the Zorvia licensing deal. The company's focus on chronic and sub-chronic therapies provides stability. A licensing agreement with Zorvia Healthcare is expected to drive margin improvements. Eris's diabetes portfolio is a major competitive differentiator, with Q2 FY27 revenue growing 18.5%, outpacing the overall Indian pharmaceutical market's growth by 240 basis points. The company is also advancing in its diabetes pipeline, with regulatory approval granted for Phase 1 and Phase 3 clinical trials of India's first recombinant semaglutide.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}